Table 3.
Logistic regression analysis of association between arylesterase activity and heart failure.
| Arylesterase activity | Non-diabetic patients | Diabetic patients | ||||||
|---|---|---|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | p for trend | Tertile 1 | Tertile 2 | Tertile 3 | p for trend | |
| Model 1a | 3.482 (1.964–6.174) | 2.615 (1.509–4.533) | 1 | <0.001 | 7.167 (2.872–17.884) | 5.584 (2.183–14.288) | 1 | <0.001 |
| Model 2b | 4.063 (2.188–7.547) | 2.960 (1.648–5.315) | 1 | <0.001 | 7.053 (2.709–18.361) | 4.876 (1.835–12.960) | 1 | <0.001 |
| Model 3c | 3.727 (1.919–7.240) | 2.939 (1.558–5.546) | 1 | <0.001 | 5.365 (1.967–14.631) | 4.236 (1.566–11.461) | 1 | 0.004 |
| Model 4d | 4.455 (2.178–9.115) | 3.637 (1.827–7.242) | 1 | <0.001 | 4.554 (1.613–12.860) | 3.846 (1.373–10.770) | 1 | 0.013 |
aUnadjusted.
bAdjusted for age, sex, history of smoking, hypertension, and previous myocardial infarction.
cModel 2 and additional adjustment for eGFR and apoA-I.
dModel 3 and additional adjustment for intake of beta-adrenergic blockers, RAAS inhibitors, and statin.